Method Optimization for the Quantification of the NAD

NAD Clinical Trial

Official title:
Method Optimization for the Quantification of the NAD (Nicotinamide Adenine Dinucleotide) Metabolome in Human Whole Blood, Plasma, and Urine, and Evaluation of Baseline Inter and Intra-subject Variability

Status Completed

Clinical Trial Summary

Method optimization for the quantification of the NAD metabolome in human whole blood, and evaluation of baseline inter and intra-subject variability.

Clinical Trial Description

Whole blood from healthy participants will be collected to optimize analytical method based on liquid chromatography tandem mass spectrometry (LC-MS/MS) for the analysis of the NAD metabolome in biological samples. Parameters such as collection volume and anti-coagulants will be investigated for optimal quantification. Moreover, inter- and intra-subject variability of NAD metabolite levels in whole blood will be evaluated. Plasma and urine will also collected for method development and variability measurements. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05561712
Study type	Observational
Source	Nestlé
Contact
Status	Completed
Phase
Start date	February 25, 2022
Completion date	March 15, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02942888` - The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition	N/A
	Active, not recruiting	`NCT06005350` - Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)	N/A